The DOI matches its Crossref record; 268 of the 268 references it cites were found in a registry or an index.
A Systematic Comparison of the Properties of Clinically Used Angiotensin II Type 1 Receptor Antagonists
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Items 201–268 of 268
Gorbea-Oppliger, V. J., Melaragno, M. G., Potter, G. S., Petit, R. L., & Fink, G. D. (1994) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)23835-6 · Cited by 36
Ouali, R., Poulette, S., Penhoat, A., & Saez, J. M. (1992) · The Journal of Steroid Biochemistry and Molecular Biology · doi:10.1016/0960-0760(92)90161-b · Cited by 35
Tagami, T., Yamamoto, H., Moriyama, K., Sawai, K., Usui, T., Shimatsu, A., & Naruse, M. (2009) · Endocrinology · doi:10.1210/en.2008-0502 · Cited by 35
Receptor-independent intracellular radical scavenging activity of an angiotensin II receptor blocker
Shao, J., Nangaku, M., Inagi, R., Kato, H., Miyata, T., Matsusaka, T., Noiri, E., & Fujita, T. (2007) · Journal of Hypertension · doi:10.1097/hjh.0b013e328165d159 · Cited by 34
Benson, S. C., Iguchi, R., Ho, C. I., Yamamoto, K. I., & Kurtz, T. W. (2008) · Journal of Hypertension · doi:10.1097/hjh.0b013e3282f56ba5 · Cited by 34
Haraguchi, T., Takasaki, K., Naito, T., Hayakawa, K., Katsurabayashi, S., Mishima, K., Iwasaki, K., & Fujiwara, M. (2009) · Neuroscience Letters · doi:10.1016/j.neulet.2009.08.043 · Cited by 34
Hypertension and coronary artery disease: cause and effect
McInnes, G. T. (1995) · Journal of Hypertension · doi:10.1097/00004872-199508001-00008 · Cited by 33
Effects of theCYP2C9*13allele on the pharmacokinetics of losartan in healthy male subjects
Li, Z., Wang, G., Wang, L., Zhang, W., Tan, Z., Fan, L., Chen, B.-L., Li, Q., Liu, J., Tu, J., et al. (2009) · Xenobiotica · doi:10.1080/00498250903134435 · Cited by 33
AT1‐receptor blockade and sympathetic neurotransmission in cardiovascular disease
Nap, A., Balt, J. C., Mathy, M. J., & van Zwieten, P. A. (2003) · Autonomic and Autacoid Pharmacology · doi:10.1111/j.1474-8673.2004.00301.x · Cited by 33
Phenobarbital minimally alters plasma concentrations of losartan and its active metabolite E-3174*
Goldberg, M. R., Lo, M. W., Deutsch, P., Wilson, S. E., McWilliams, E. J., & McCrea, J. B. (1996) · Clinical Pharmacology & Therapeutics · doi:10.1016/s0009-9236(96)80004-x · Cited by 33
Bähr, I. N., Tretter, P., Krüger, J., Stark, R. G., Schimkus, J., Unger, T., Kappert, K., Scholze, J., Parhofer, K. G., & Kintscher, U. (2011) · Hypertension · doi:10.1161/hypertensionaha.111.173542 · Cited by 33
Pharmacoeconomic challenges in disease management of hypertension.
Ambrosioni, E. (2001) · PubMed · Cited by 33
Sanni, S. J., Hansen, J. H., Bonde, M., Speerschneider, T., Christensen, G., Munk, S., Gammeltoft, S., & Hansen, J. (2010) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2010.00875.x · Cited by 32
Fukuda, D., Enomoto, S., Hirata, Y., Nagai, R., & Sata, M. (2010) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2010.09.014 · Cited by 32
Sugimoto, K., Kazdová, L., Qi, N., Hyakukoku, M., Křen, V., Šimáková, M., Zı́dek, V., Kurtz, T. W., & Pravenec, M. (2008) · Journal of Hypertension · doi:10.1097/hjh.0b013e3282f9b58a · Cited by 32
Kario, K., Yano, Y., Matsuo, T., Hoshide, S., Asada, Y., & Shimada, K. (2011) · Journal of Hypertension · doi:10.1097/hjh.0b013e32834cf1c0 · Cited by 32
Choi, C., Kim, M., Chung, E.-K., Lee, H.-I., Jang, C., Bae, J., & Lee, S. (2011) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-011-1098-0 · Cited by 32
Modification of pressure natriuresis by long-term losartan in spontaneously hypertensive rats.
Kline, R. L., & Liu, F. (1994) · Hypertension · doi:10.1161/01.hyp.24.4.467 · Cited by 32
Pharmacokinetic and pharmacodynamic interaction of single doses of valsartan and atenolol
Czendlik, C., Sioufi, A., Preiswerk, G., & HOWALD, H. (1997) · European Journal of Clinical Pharmacology · doi:10.1007/s002280050318 · Cited by 31
The Impact of Hepatic Uptake on the Pharmacokinetics of Organic Anions
Gardiner, P., & Paine, S. W. (2011) · Drug Metabolism and Disposition · doi:10.1124/dmd.111.039842 · Cited by 31
Angiotensin II antagonism and plasma radioreceptor‐kinetics of candesartan in man
Malerczyk, C., Fuchs, B., Belz, G. G., Roll, S., Butzer, R., Breithaupt‐Grögler, K., Herrmann, V., Sg, M., Högemann, A., Voith, B., et al. (1998) · British Journal of Clinical Pharmacology · doi:10.1046/j.1365-2125.1998.00722.x · Cited by 30
Comparative Pharmacodynamics and Pharmacokinetics of Candesartan and Losartan in Man
Fuchs, B., Breithaupt‐Grögler, K., Belz, G. G., Roll, S., Malerczyk, C., Herrmann, V., Spahn-Langguth, H., & Mutschler, E. (2000) · Journal of Pharmacy and Pharmacology · doi:10.1211/0022357001774994 · Cited by 29
Peripherally applied candesartan inhibits central responses to angiotensin II in conscious rats
Gohlke, P., Kox, T., Jürgensen, T., et al. (2002) · Naunyn-Schmiedeberg s Archives of Pharmacology · doi:10.1007/s00210-002-0545-y · Cited by 29
Losartan Does Not Affect the Pharmacokinetics and Pharmacodynamics of Warfarin
Kong, A. T., Tomasko, L., Waldman, S. A., Osborne, B., Deutsch, P., Goldberg, M. R., & Bjornsson, T. D. (1995) · The Journal of Clinical Pharmacology · doi:10.1002/j.1552-4604.1995.tb04018.x · Cited by 29
Yamashita, F., Ohtani, H., Koyabu, N., Ushigome, F., Satoh, H., 村上, 秀., Uchiumi, T., Nakamura, T., Kuwano, M., Tsujimoto, M., et al. (2006) · Journal of Pharmacy and Pharmacology · doi:10.1211/jpp.58.11.0011 · Cited by 28
Goldberg, M. R., Lo, M. W., Bradstreet, T. E., Ritter, M., & H�gland, P. (1995) · European Journal of Clinical Pharmacology · doi:10.1007/bf00192369 · Cited by 27
Telmisartan inhibits β2-integrin MAC-1 expression in human T-lymphocytes
Link, A., Lenz, M., Legner, D., Böhm, M., & Nickenig, G. (2006) · Journal of Hypertension · doi:10.1097/01.hjh.0000242415.73406.17 · Cited by 27
Morgan, J. M., Palmisano, M., Piraino, A. J., et al. (1997) · Clinical Pharmacology & Therapeutics · doi:10.1016/s0009-9236(97)90180-6 · Cited by 27
Arsenault, J., Lehoux, J., Lanthier, L., Cabana, J., Guillemette, G., Lavigne, P., Leduc, R., & Escher, E. (2010) · Pharmacogenetics and Genomics · doi:10.1097/fpc.0b013e32833a6d4a · Cited by 26
Yoshida, T., Yamagishi, S., Matsui, T., Nakamura, K., Ueno, T., Takeuchi, M., & Sata, M. (2008) · Journal of International Medical Research · doi:10.1177/147323000803600204 · Cited by 25
Angiotensin II signaling activates the NO-cGMP pathway in rat proximal tubules
Zhang, C., & Mayeux, P. R. (1998) · Life Sciences · doi:10.1016/s0024-3205(98)00278-1 · Cited by 24
Burnett, J. (1997) · Journal of Human Hypertension · doi:10.1038/sj.jhh.1000400 · Cited by 24
Evaluation of a pharmacokinetic interaction between valsartan and simvastatin in healthy subjects
Sunkara, G., Reynolds, C., Pommier, F., Humbert, H., Yeh, C. M., & Prasad, P. (2007) · Current Medical Research and Opinion · doi:10.1185/030079906x167471 · Cited by 24
Stangier, J., Su, C. P. F., Fraunhofer, A., & Tetzloff, W. (2000) · The Journal of Clinical Pharmacology · doi:10.1177/009127000004001205 · Cited by 23
Toba, H., Tojo, C., Wang, J., Noda, K., Kobara, M., & Nakata, T. (2012) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2012.01.026 · Cited by 23
Inada, Y., Ojima, M., Kanagawa, R., Misumi, Y., Nishikawa, K., & Naka, T. (1999) · Journal of Human Hypertension · doi:10.1038/sj.jhh.1000749 · Cited by 23
The type 1 angiotensin-II receptor mediates intracellular calcium mobilization in rat luteal cells.
Pepperell, J. R., Németh, G., Yamada, Y., et al. (1993) · Endocrinology · doi:10.1210/endo.133.4.8404609 · Cited by 23
Kiya, Y., Miura, S.-I., Fujino, M., et al. (2010) · Clinical and Experimental Hypertension · doi:10.3109/10641960903254430 · Cited by 23
Tanigawara, Y., Yoshihara, K., Kuramoto, K., & Arakawa, K. (2009) · Drug Metabolism and Pharmacokinetics · doi:10.2133/dmpk.24.376 · Cited by 22
Iwai, M., Chen, R., Ide, A., Iwanami, J., Tomochika, H., Tomono, Y., Mogi, M., & Horiuchi, M. (2006) · Journal of Hypertension · doi:10.1097/01.hjh.0000244952.54738.f6 · Cited by 21
Huwiler, A., van Rossum, G. S. A. T., Wartmann, M., & Pfeilschifter, J. M. (1998) · European Journal of Pharmacology · doi:10.1016/s0014-2999(97)01542-2 · Cited by 21
Characterization of [3H]losartan receptors in isolated rat glomeruli
Chansel, D., Vandermeersch, S., Pham, P., et al. (1993) · European Journal of Pharmacology Molecular Pharmacology · doi:10.1016/0922-4106(93)90077-m · Cited by 20
Pharmacokinetic drug interaction studies with candesartan cilexetil.
Jonkman, J. H., van Lier, J. J., van Heiningen, P. N. M., Lins, R. L., Sennewald, R., & Högemann, A. (1997) · PubMed · Cited by 19
Stangier, J., Su, C. P. F., Hendriks, M. G. C., van Lier, J. J., Sollie, F. A. E., Oosterhuis, B., & Jonkman, J. H. G. (2000) · The Journal of Clinical Pharmacology · doi:10.1177/009127000004001204 · Cited by 19
Pharmacokinetics of Olmesartan Medoxomil plus Hydrochlorothiazide Combination in Healthy Subjects
Kreutz, R. H., Bolbrinker, J., & Huber, M. (2006) · Clinical Drug Investigation · doi:10.2165/00044011-200626010-00004 · Cited by 19
Characterization of cardiac angiotensin AT1 receptors by [3H]SR 47436
Delisée, C., Schaeffer, P., Cazaubon, C., & Chatelain, P. (1993) · European Journal of Pharmacology Molecular Pharmacology · doi:10.1016/0922-4106(93)90071-g · Cited by 18
A non-competitive type of angiotensin-receptor antagonism by losartan in renal artery preparations
Zhang, J., Pfaffendorf, M., Zhang, J., et al. (1994) · European Journal of Pharmacology · doi:10.1016/0014-2999(94)90183-x · Cited by 18
Telmisartan Increases the Permeability of Endothelial Cells through Zonula Occludens-1
Bian, C., Wu, Y., & Chen, P. (2009) · Biological and Pharmaceutical Bulletin · doi:10.1248/bpb.32.416 · Cited by 18
Martineau, D., Yamaguchi, N., & Briand, R. (1995) · Canadian Journal of Physiology and Pharmacology · doi:10.1139/y95-058 · Cited by 17
Miura, M., Satoh, S., Kagaya, H., Saito, M., Inoue, T., Ohkubo, T., Habuchi, T., & Suzuki, T. (2009) · Journal of Clinical Pharmacy and Therapeutics · doi:10.1111/j.1365-2710.2009.01053.x · Cited by 16
Hsueh, W. A., Davidai, G., Henry, R. R., & Mudaliar, S. R. D. (2010) · Journal of Clinical Hypertension · doi:10.1111/j.1751-7176.2010.00335.x · Cited by 16
Hines, J., Fluharty, S. J., & Sakai, R. R. (1999) · European Journal of Pharmacology · doi:10.1016/s0014-2999(99)00662-7 · Cited by 16
Antagonizing the angiotensin II subtype I receptor: A focus on olmesartan medoxomil
Nussberger, J., & Koike, H. (2004) · Clinical Therapeutics · doi:10.1016/s0149-2918(04)90141-5 · Cited by 15
Fabiani, M. E., Dinh, D. T., Nassis, L., CASLEY, D. J., & Johnston, C. I. (2000) · Clinical Science · doi:10.1042/cs0990331 · Cited by 15
Ogihara, T., Nagano, M., Higaki, J., et al. (1995) · Journal of Cardiovascular Pharmacology · doi:10.1097/00005344-199509000-00021 · Cited by 14
de Mey, C., Beithaupt, K., Palm, D., Fuhr, U., & Belz, G. G. (1993) · European Journal of Clinical Pharmacology · doi:10.1007/bf00316470 · Cited by 14
Bhuiyan, M. A., Hossain, M., Miura, S.-I., Nakamura, T., Ozaki, M., & Nagatomo, T. (2009) · Journal of Pharmacological Sciences · doi:10.1254/jphs.09202fp · Cited by 13
Sandwall, P., Lo, M.-W., Jonzon, B., et al. (1999) · European Journal of Clinical Pharmacology · doi:10.1007/s002280050629 · Cited by 12
Abdelrahman, A., & Pang, C. C. Y. (1992) · Canadian Journal of Physiology and Pharmacology · doi:10.1139/y92-093 · Cited by 12
Eprosartan Does Not Affect the Pharmacodynamics of Warfarin
Kazierad, D. J., Martin, D. E., Ilson, B. E., Boike, S. C., Zariffa, N. M.-D., Forrest, A., & Jorkasky, D. K. (1998) · The Journal of Clinical Pharmacology · doi:10.1002/j.1552-4604.1998.tb04473.x · Cited by 11
Huber, M., Bolbrinker, J., & Kreutz, R. H. (2006) · Clinical and Experimental Hypertension · doi:10.1080/10641960600946171 · Cited by 8
Kumar, V. V. P., & Srinivas, N. R. (2008) · European Journal of Drug Metabolism and Pharmacokinetics · doi:10.1007/bf03190880 · Cited by 8
Tsukamoto, O., & Kitakaze, M. (2011) · Cardiovascular Drugs and Therapy · doi:10.1007/s10557-011-6361-1 · Cited by 7
Endo, S., Fukahori, A., Tokuhiro, S., Shinagawa, A., Walker, J. R., Yoshihara, K., Ishizuka, H., Ieiri, I., & Sugiyama, Y. (2012) · Journal of Human Genetics · doi:10.1038/jhg.2012.63 · Cited by 7
Lambert, D. G., Champion, H. C., & Kadowitz, P. J. (1998) · PubMed · Cited by 5
Bhuiyan, M. A., Hossain, M., Nakamura, T., Ozaki, M., & Nagatomo, T. (2010) · Journal of Pharmacological Sciences · doi:10.1254/jphs.09343sc · Cited by 5
Lambert, D. G., Champion, H. C., & Kadowitz, P. J. (1998) · Canadian Journal of Physiology and Pharmacology · doi:10.1139/y98-002 · Cited by 4
Lambert, D. G., Champion, H. C., & Kadowitz, P. J. (1998) · Canadian Journal of Physiology and Pharmacology · doi:10.1139/cjpp-76-2-133 · Cited by 1
Cited by
Vitaku, E., Smith, D. T., & Njardarson, J. T. (2014) · Journal of Medicinal Chemistry · doi:10.1021/jm501100b · Cited by 6,418
Chauhan, V. P., Martin, J. D., Liu, H., Lacorre, D. A., Jain, S. R., Kozin, S. V., Stylianopoulos, T., Mousa, A. S., Han, X., Adstamongkonkul, P., et al. (2013) · Nature Communications · doi:10.1038/ncomms3516 · Cited by 1,031
Singh, K. D., & Karnik, S. S. (2020) · GPCRs · doi:10.1016/b978-0-12-816228-6.00020-9 · Cited by 704
Daniele, S. G., Béraud, D., Davenport, C., Cheng, K., Yin, H., & Maguire-Zeiss, K. A. (2015) · Science Signaling · doi:10.1126/scisignal.2005965 · Cited by 303
Karnik, S. S., Unal, H., Kemp, J. R., Tirupula, K. C., Eguchi, S., Vanderheyden, P. M. L., & Thomas, W. G. (2015) · Pharmacological Reviews · doi:10.1124/pr.114.010454 · Cited by 302
Metadata
- Authors
- Michel, M. C., Foster, C., Brunner, H. R., & Liu, L.
- Venue
- Pharmacological Reviews
- Publisher
- Elsevier BV
- Published
- 2013-04
- Volume
- 65
- Issue
- 2
- Pages
- 809-848
- ISSN
- 0031-6997 (ISSN-L)
- OpenAlex
- W2097957153
- Cited by
- 301
- References
- 268
- FWCI
- 18.01
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.